Literature DB >> 25483786

Recurrence and cancer-specific survival according to the expression of IL-4Rα and IL-13Rα1 in patients with oral cavity cancer.

Minsu Kwon1, Ji Won Kim1, Jong-Lyel Roh2, Yangsoon Park3, Kyung-Ja Cho3, Seung-Ho Choi1, Soon Yuhl Nam1, Sang Yoon Kim4, Byung-Heon Lee5.   

Abstract

BACKGROUND: Interleukin-4 (IL-4) and interleukin-13 (IL-13) are anti-inflammatory and immunomodulatory cytokines that play crucial roles in cancer progression. However, the clinical significance of the expression of these cytokines and their receptors (IL-4R) in oral cavity squamous cell carcinoma (OSCC) is unknown. Therefore, we evaluated the expression of IL-4R in OSCC specimens by immunohistochemistry (IHC) and analysed its relationship to recurrence and survival.
METHODS: A total of 186 patients with OSCC were enrolled, and the expression of IL-4Rα and IL-13Rα1 on their primary tumour specimens was evaluated by IHC and correlated to clinicopathologic parameters, recurrence and survival.
FINDINGS: High expression of IL-4Rα and IL-13Rα1 was observed in 60 (32.3%) and 165 (88.7%) patients, respectively. IL-4Rα expression was inversely correlated with parameters reflecting primary tumour burden, including tumour size, tumour stage and depth of invasion at the initial diagnosis (P < 0.05). High expression of IL-4Rα also correlated with a greater risk of recurrence (P = 0.002), but was unrelated to cancer-specific survival (CSS, P = 0.118). Conversely, high IL-13Rα1 expression correlated with reduced recurrence (P < 0.001) and increased CSS (P < 0.001) in OSCC patients. INTERPRETATIONS: High expression of IL-4Rα correlated with increased recurrence, while high IL-13Rα1 expression had an inverse relationship to recurrence and CSS in OSCC patients.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Interleukin-13 receptor; Interleukin-4 receptor; Oral cavity squamous cell carcinoma; Recurrence; Survival

Mesh:

Substances:

Year:  2014        PMID: 25483786     DOI: 10.1016/j.ejca.2014.11.010

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Oral sampling methods are associated with differences in immune marker concentrations.

Authors:  Carole Fakhry; Fares Qeadan; Robert H Gilman; Pablo Yori; Margaret Kosek; Nicole Patterson; David W Eisele; Christine G Gourin; Chandala Chitguppi; Morgan Marks; Patti Gravitt
Journal:  Laryngoscope       Date:  2017-11-24       Impact factor: 3.325

Review 2.  Role of tumour-associated macrophages in oral squamous cells carcinoma progression: an update on current knowledge.

Authors:  Maria Noel Marzano Rodrigues Petruzzi; Karen Cherubini; Fernanda Gonçalves Salum; Maria Antonia Zancanaro de Figueiredo
Journal:  Diagn Pathol       Date:  2017-04-05       Impact factor: 2.644

3.  Expression of IL4Rα and IL13Rα1 are associated with poor prognosis of soft-tissue sarcoma of the extremities, superficial trunk, and retroperitoneum.

Authors:  Kyoung Min Kim; Usama Khamis Hussein; See-Hyoung Park; Young Jae Moon; Zhongkai Zhang; Asmaa Gamal Ahmed; Ae-Ri Ahn; Ho Sung Park; Jung Ryul Kim; Kyu Yun Jang
Journal:  Diagn Pathol       Date:  2021-01-09       Impact factor: 2.644

4.  IL-13Rα2 gene expression is a biomarker of adverse outcome in patients with adrenocortical carcinoma.

Authors:  Abhinav Kumar; Ian H Bellayr; Hridaya S Singh; Raj K Puri
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.240

5.  IL4Rα and IL13Rα1 Are Involved in the Development of Human Gallbladder Cancer.

Authors:  Sung Woo Ahn; Chang Min Lee; Mi-Ae Kang; Usama Khamis Hussein; Ho Sung Park; Ae-Ri Ahn; Hee Chul Yu; Jae Do Yang; Yung-Hun Yang; Kyungmoon Park; Jongsung Lee; Kyu Yun Jang; See-Hyoung Park
Journal:  J Pers Med       Date:  2022-02-09

6.  IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice.

Authors:  Mian Xie; Xiao-jun Wu; Jin-jun Zhang; Chao-sheng He
Journal:  Oncotarget       Date:  2015-10-20

7.  The Expression Levels of IL-4/IL-13/STAT6 Signaling Pathway Genes and SOCS3 Could Help to Differentiate the Histopathological Subtypes of Non-Small Cell Lung Carcinoma.

Authors:  Dorota Pastuszak-Lewandoska; Daria Domańska-Senderowska; Adam Antczak; Jacek Kordiak; Paweł Górski; Karolina H Czarnecka; Monika Migdalska-Sęk; Ewa Nawrot; Justyna M Kiszałkiewicz; Ewa Brzeziańska-Lasota
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.